BNTC: Benitec Biopharma Inc. Stock

by  •  • Comments Off on BNTC: Benitec Biopharma Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 347.87
Enterprise Value ($M) 269.59
Book Value ($M) 75.94
Book Value / Share 2.98
Price / Book 4.58
NCAV ($M) 75.59
NCAV / Share 2.96
Price / NCAV 4.60

Profitability (mra)
Return on Invested Capital (ROIC) -0.28
Return on Assets (ROA) -1.43
Return on Equity (ROE) -1.86

Liquidity (mrq)
Quick Ratio 25.48
Current Ratio 25.48

Balance Sheet (mrq) ($M)
Current Assets 78.71
Assets 79.07
Liabilities 3.13
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
03-28 13D/A Suvretta Capital Management, Llc 49.90 9.03
02-14 13G/A Janus Henderson Group Plc 11.30 -2.82
02-13 13G/A HBM Healthcare Investments (Cayman) Ltd. 4.50 0.00
01-27 13G/A Franklin Resources Inc 18.10
11-14 13G Nantahala Capital Management, LLC 9.65
2024-04-11 13G/A Adage Capital Partners Gp, L.l.c. 9.99 39.81

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPOR
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-09-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2024 ☐ Transition Report under Sect
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 10,178 31,340 32.48
2025-04-16 10,035 43,121 23.27
2025-04-15 12,380 34,973 35.40
2025-04-14 2,678 12,631 21.20

(click for more detail)

Similar Companies
BGM – BGM Group Ltd. BIVI – BioVie Inc.
BMRA – Biomerica, Inc. BOLT – Bolt Biotherapeutics, Inc.
BON – Bon Natural Life Limited


Financial data and stock pages provided by
Fintel.io